Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS ...

The Japan Early-stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) is an investigator-initiated study conducted ...

Biopharmaceutical company Trace Neuroscience announced it has raised $101 million in a Series A financing effort to develop ...

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

Amyotrophic Lateral Sclerosis (ALS) Treatment Market size was valued at USD 713.3 million in 2023 and is expected to grow at a CAGR of 5.5% from 2024 to 2032. This growth is driven by the ...

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...

Report Ocean, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023.

PLL Therapeutics focuses on restoring gut permeability. Its initial indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. The company’s therapy, PLL001, consists of several ...

Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS), an incurable degenerative neurological disorder that leads to muscle ...

Citation: Study identifies 51 amyotrophic lateral sclerosis-associated mutations that could help diagnose the disease (2024, October 31) retrieved 16 November 2024 from https://medicalxpress.com ...